Results 11 to 20 of about 4,076 (204)

Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. [PDF]

PLoS ONE, 2011
Levetiracetam is an FDA-approved drug used to treat epilepsy and other disorders of the nervous system. Although it is known that levetiracetam binds the synaptic vesicle protein SV2A, how drug binding affects synaptic functioning remains unknown.
Amy Nowack, Erik B Malarkey, Jia Yao, Adam Bleckert, Jessica Hill, Sandra M Bajjalieh   +5 more
doaj   +5 more sources

SV2A-PET in a tauopathy mouse model

Nuklearmedizin - NuclearMedicine, 2023
Ziel/Aim Transgenic mouse models are frequently used to study the mechanismsof neurodegenerative diseases and possible therapeutic options. Weinvestigated the tauopathy mouse model TauRDΔK, which expresses the repeatdomain of human tau with deletion of ...
H. Endepols, E. M. Mandelkow, E. Mandelkow, D. Schneider, B. Neumaier, A. Drzezga   +5 more
openaire   +2 more sources

SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release [PDF]

Neuron, 1999
SV2 proteins are abundant synaptic vesicle proteins expressed in two major (SV2A and SV2B) and one minor isoform (SV2C) that resemble transporter proteins. We now show that SV2B knockout mice are phenotypically normal while SV2A- and SV2A/SV2B double knockout mice exhibit severe seizures and die postnatally.
Janz, Roger, Goda, Yukiko, Geppert, Martin, Missler, Markus, Südhof, Thomas C   +4 more
openaire   +3 more sources

Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET) [PDF]

European Journal of Nuclear Medicine and Molecular Imaging, 2022
Exploring synaptic density changes during brain growth is crucial to understanding brain development. Previous studies in nonhuman primates report a rapid increase in synapse number between the late gestational period and the early neonatal period, such that synaptic density approaches adult levels by birth.
Samantha Rossano, Takuya Toyonaga, Eric Berg, Isabella Lorence, Krista Fowles, Nabeel Nabulsi, Jim Ropchan, Songye Li, Yunpeng Ye, Zachary Felchner, David Kukis, Yiyun Huang, Helene Benveniste, Alice F. Tarantal, Stephanie Groman, Richard E. Carson   +15 more
openaire   +5 more sources

Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia

Schizophrenia Research, 2012
Convergent evidence from pharmacological and animal studies suggests a possible role for the synaptic vesicle glycoprotein 2A gene (SV2A) in schizophrenia susceptibility. To test systematically all common variants in the SV2A gene region for an association with schizophrenia, we used a HapMap-based haplotype tagging approach and tested five SNPs in 794
Mattheisen, Manuel, Muehleisen, Thomas W., Strohmaier, Jana, Treutlein, Jens, Nenadic, Igor, Alblas, Margrieta, Meier, Sandra, Degenhardt, Franziska A., Herms, Stefan, Hoffmann, Per, Witt, Stephanie H., Giegling, Ina, Sauer, Heinrich, Schulze, Thomas G., Rujescu, Dan, Noethen, Markus M., Rietschel, Marcella, Cichon, Sven   +17 more
core   +6 more sources

A missense mutation of the gene encoding synaptic vesicle glycoprotein 2A (SV2A) confers seizure susceptibility by disrupting amygdalar synaptic GABA release [PDF]

Frontiers in Pharmacology, 2016
Synaptic vesicle glycoprotein 2A (SV2A) is specifically expressed in the membranes of synaptic vesicles and modulates action potential-dependent neurotransmitter release. To explore the role of SV2A in the pathogenesis of epileptic disorders, we recently
Kentaro Tokudome, Takahiro Okumura, Ryo Terada, Saki Shimizu, Naofumi Kunisawa, Tomoji Mashimo, Tomoji Mashimo, Tadao Serikawa, Tadao Serikawa, Masashi Sasa, Yukihiro Ohno   +10 more
doaj   +2 more sources

Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A

Nature Communications
More than one percent of people have epilepsy worldwide. Levetiracetam (LEV) is a successful new-generation antiepileptic drug (AED), and its derivative, brivaracetam (BRV), shows improved efficacy.
Atsushi Yamagata, Kaori Ito, Takehiro Suzuki, Naoshi Dohmae, Tohru Terada, Mikako Shirouzu   +5 more
doaj   +3 more sources

Structures of native SV2A reveal the binding mode for tetanus neurotoxin and anti-epileptic racetams

Nature Communications
The synaptic vesicle glycoprotein 2A (SV2A) is a synaptic vesicle (SV) resident with homology to the major facilitator superfamily (MFS) and essential in vertebrate neurotransmission.
Stephan Schenck, Toon Laeremans, Jan Steyaert, Janine D. Brunner   +3 more
doaj   +2 more sources

Rare protein sequence variation in SV2A gene does not affect response to levetiracetam

Epilepsy Research, 2012
Levetiracetam, a broad spectrum antiepileptic drug, binds to membrane protein SV2A. The protein coding region of SV2A was sequenced in 158 patients with focal or generalized epilepsies divided into three groups based on their response to levetiracetam: responders (>75% decrease), exacerbators (50% increase) and non-responders.
Dibbens, L., Hodgson, B., Helbig, K., Oliver, K., Mulley, J., Berkovic, S., Scheffer, I.   +6 more
openaire   +4 more sources

Anxiety-like features and spatial memory problems as a consequence of hippocampal SV2A expression. [PDF]

PLoS ONE, 2019
The Synaptic Vesicle Protein 2A (SV2A) is a transmembrane protein whose presence is reduced both in animal models and in patients with chronic epilepsy. Besides its implication in the epileptic process, the behavioural consequences of the changes in its ...
Maria Elisa Serrano, Odile Bartholomé, Priscilla Van den Ackerveken, André Ferrara, Bernard Rogister, Alain Plenevaux, Ezio Tirelli   +6 more
doaj   +2 more sources